2-氰基-4-吡啶乙酸 | 502509-05-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氰基-4-吡啶乙酸
• 英文名称: 2-(2-cyanopyridin-4-yl)acetic acid
• CAS: 502509-05-9
• 化学式: C₈H₆N₂O₂
• mdl: MFCD07367938
• 分子量: 162.148
• InChiKey: RUHXLBCLPMDMFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  74
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-氰基-4-吡啶乙酸 、 2-(9H-carbazol-1-yl)aniline 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以73%的产率得到N-(2-(9H-carbazol-1-yl)phenyl)-2-(2-cyanopyridin-4-yl)acetamide
  参考文献：
  名称：

  发现一种新型的变构抑制剂骨架，用于多腺苷二磷酸核糖聚合酶14（PARP14）大结构域2。

  摘要：

  聚腺苷二磷酸核糖聚合酶14（PARP14）已牵涉到DNA损伤反应途径中的同源重组。PARP14包含三个（ADP核糖结合）宏域（MD），尚不清楚其对病理学中整个PARP14功能的确切贡献。中等通量筛选导致鉴定出N-（2（-9H-咔唑-1-基）苯基）乙酰胺（GeA-69，1）作为新型变构PARP14 MD2（PARP14的第二个MD）抑制剂。我们在此报告了围绕这种新型化学型的药物化学，以提供亚微摩尔的PARP14 MD2抑制剂。该化学系列为进一步开发PARP14化学探针提供了新的起点。

  DOI：

  10.1016/j.bmc.2018.03.020

文献信息

• [EN] MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN<br/>[FR] MODULATEURS DE LA PROTÉINE PROTO-ONCOGÈNE DE LA FAMILLE MYC
  申请人：NALO THERAPEUTICS

  公开号：WO2022046861A1

  公开（公告）日：2022-03-03

  Disclosed herein are compounds and compositions having potency in the modulation of Myc family proteins. Such compounds and compositions can be used in the treatment of proliferative diseases, such as cancer, or in the treatment of disease where modulation of Myc family proteins is desired. Also disclosed herein are methods of using said compounds and compositions.

  本文中披露了具有调节Myc家族蛋白活性的药物和配方。这些药物和配方可用于治疗增生性疾病，如癌症，或治疗需要调节Myc家族蛋白的疾病。本文还披露了使用上述药物和配方的方法。
• Inhibitors of the acetyltransferase domain of N-acetylglucosamine-1-phosphate-uridylyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU). Part 2: Optimization of physical properties leading to antibacterial aryl sulfonamides
  作者：Suzanne S. Stokes、Robert Albert、Ed T. Buurman、Beth Andrews、Adam B. Shapiro、Oluyinka M. Green、Andrew R. McKenzie、Ludovic R. Otterbein

  DOI：10.1016/j.bmcl.2012.10.003

  日期：2012.12

  A previously described aryl sulfonamide series, originally found through HTS, targets GlmU, a bifunctional essential enzyme involved in bacterial cell wall synthesis. Using structure-guided design, the potency of enzyme inhibition was increased in multiple isozymes from different bacterial species. Unsuitable physical properties (low Log D and high molecular weight) of those compounds prevented them from entering the cytoplasm of bacteria and inhibiting cell growth. Further modifications described herein led to compounds that possessed antibacterial activity, which was shown to occur through inhibition of GlmU. The left-hand side amide and the right-hand side sulfonamides were modified such that enzyme inhibitory activity was maintained (IC50 <0.1 mu M against GlmU isozymes from Gram-negative organisms), and the lipophilicity was increased giving compounds with Log D -1 to 3. Antibacterial activity in an efflux-pump deficient mutant of Haemophilus influenzae resulted for compounds such as 13. (C) 2012 Elsevier Ltd. All rights reserved.